Syndax: Overview of Fourth Quarter Financial Results

Syndax Pharmaceuticals Reports Fourth Quarter Financial Results

Syndax Pharmaceuticals Inc., headquartered in New York, announced a fourth-quarter net loss totaling $68 million.

The company indicated that this equates to a loss of 78 cents per share.

These figures fell short of analyst projections, as the consensus from six experts polled by Zacks Investment Research anticipated a loss of 64 cents per share.

Despite the loss, Syndax generated $68.7 million in revenue during the quarter, exceeding expectations. Four analysts surveyed by Zacks had forecasted revenue of $62.4 million.